Back to search

Article

The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular disease

2023-07-28

Abstract excerpt

<title>Abstract</title> <p>Sclerostin inhibitors protect against osteoporotic fractures, but their cardiovascular safety remains unclear. We conducted a <italic>cis</italic>-Mendelian randomisation analysis to study the effect of sclerostin levels on cardiovascular risk factors. We meta-analysed three GWAS of sclerostin levels including 49,568 Europeans. Public GWAS were used for study outcomes, with findings val...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
dc671dcb-5c16-5c71-9c28-9c7de9c2a7ca
DOI
10.21203/rs.3.rs-3209943/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The cause-effect relationship between sclerostin levels, cardiovascular biomarkers, risk factors, and cardiovascular diseaseDOI 10.21203/rs.3.rs-3209943/v1
Effect of genetically predicted sclerostin on cardiovascular biomarkers, risk factors, and disease outcomes.Semantic proximity
Lifelong genetically lowered sclerostin and risk of cardiovascular diseaseSemantic proximity
Lowering of circulating sclerostin may increase risk of atherosclerosis and its risk factors: evidence from a genome-wide association meta-analysis followed by Mendelian randomizationSemantic proximity
Observational and Mendelian randomization studies of plasma sclerostin levels do not provide evidence of cardiovascular adverse effects of sclerostin inhibition.Semantic proximity
Lowering of Circulating Sclerostin May Increase Risk of Atherosclerosis and Its Risk Factors: Evidence From a Genome-Wide Association Meta-Analysis Followed by Mendelian Randomization.Semantic proximity
Sclerostin and Cardiovascular DiseaseSemantic proximity
Role of Sclerostin in Cardiovascular SystemSemantic proximity
A novel and efficient machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibitionSemantic proximity
Sclerostin Downregulation Globally by Naturally Occurring Genetic Variants, or Locally in Atherosclerotic Plaques, Does Not Associate With Cardiovascular Events in HumansSemantic proximity
The sclerostin story: From human genetics to the development of novel anabolic treatment for osteoporosisSemantic proximity
A flexible machine learning Mendelian randomization estimator applied to predict the safety and efficacy of sclerostin inhibition.Semantic proximity
From skeletal to cardiovascular disease in 12 steps—the evolution of sclerostin as a major player in CKD-MBDSemantic proximity
Select a neighboring publication to make it the new centre.